Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.

Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND.

Clin Cancer Res. 2018 Nov 1;24(21):5225-5232. doi: 10.1158/1078-0432.CCR-18-0564. Epub 2018 Jul 16.

PMID:
30012563
2.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
3.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R.

Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.

4.

Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.

Morris MJ, Rathkopf DE, Novotny W, Gibbons JA, Peterson AC, Khondker Z, Ouatas T, Scher HI, Fleming MT.

Clin Cancer Res. 2016 Aug 1;22(15):3774-81. doi: 10.1158/1078-0432.CCR-15-2638. Epub 2016 Feb 8.

5.

Sequential Therapy in Metastatic Renal Cell Carcinoma.

Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, Fleming MT, Vogelzang NJ.

J Kidney Cancer VHL. 2016 Apr 5;3(1):23-35. doi: 10.15586/jkcvhl.2016.46. eCollection 2016. Review.

6.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G.

Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. Epub 2015 Sep 9.

PMID:
26362343
7.

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM.

Clin Genitourin Cancer. 2012 Mar;10(1):6-14. doi: 10.1016/j.clgc.2011.11.003.

PMID:
22340631
8.

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.

Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L.

Ann Oncol. 2012 Jul;23(7):1803-8. doi: 10.1093/annonc/mdr555. Epub 2011 Nov 23.

PMID:
22112969
9.

Event-related potentials: search for positive and negative child-related schemata in individuals at low and high risk for child physical abuse.

Milner JS, Rabenhorst MM, McCanne TR, Crouch JL, Skowronski JJ, Fleming MT, Hiraoka R, Risser HJ.

Child Abuse Negl. 2011 Apr;35(4):249-66. doi: 10.1016/j.chiabu.2011.01.002. Epub 2011 Apr 9.

PMID:
21481458
10.

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD.

Urol Oncol. 2011 Nov-Dec;29(6):682-9. doi: 10.1016/j.urolonc.2009.09.015. Epub 2009 Dec 3.

PMID:
19959380
11.

Increasing vaccination rates among health care workers using unit "champions" as a motivator.

Slaunwhite JM, Smith SM, Fleming MT, Strang R, Lockhart C.

Can J Infect Control. 2009 Fall;24(3):159-64.

PMID:
19891169
12.

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE.

Ann Oncol. 2010 Feb;21(2):319-24. doi: 10.1093/annonc/mdp323. Epub 2009 Jul 24.

PMID:
19633050
13.

Genetics, gene expression and bioinformatics of the pituitary gland.

Davis SW, Potok MA, Brinkmeier ML, Carninci P, Lyons RH, MacDonald JW, Fleming MT, Mortensen AH, Egashira N, Ghosh D, Steel KP, Osamura RY, Hayashizaki Y, Camper SA.

Horm Res. 2009 Apr;71 Suppl 2:101-15. doi: 10.1159/000192447. Epub 2009 Apr 29.

14.

Trial design for metastatic castration-resistant prostate cancer.

Sonpavde G, Fleming MT, Hutson TE, Galsky MD.

J Clin Oncol. 2008 Jul 20;26(21):3647-8; author reply 3648-9. doi: 10.1200/JCO.2008.17.1140. No abstract available.

PMID:
18640946
15.

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

Fleming MT, Morris MJ, Heller G, Scher HI.

Nat Clin Pract Oncol. 2006 Dec;3(12):658-67. Review.

PMID:
17139317
16.

Pharmacokinetics and toxicity of weekly docetaxel in older patients.

Hurria A, Fleming MT, Baker SD, Kelly WK, Cutchall K, Panageas K, Caravelli J, Yeung H, Kris MG, Gomez J, Miller VA, D'Andrea G, Scher HI, Norton L, Hudis C.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6100-5.

17.

De novo exon duplication in a new allele of mouse Glra1 (spasmodic).

Holland KD, Fleming MT, Cheek S, Moran JL, Beier DR, Meisler MH.

Genetics. 2006 Dec;174(4):2245-7. Epub 2006 Oct 8.

18.

Effects of method on participants and disclosure rates in research on sensitive topics.

Reddy MK, Fleming MT, Howells NL, Rabenhorst MM, Casselman R, Rosenbaum A.

Violence Vict. 2006 Aug;21(4):499-506.

PMID:
16897916
19.

A comparison of methods for collecting self-report data on sensitive topics.

Rosenbaum A, Rabenhorst MM, Reddy MK, Fleming MT, Howells NL.

Violence Vict. 2006 Aug;21(4):461-71.

PMID:
16897913
20.

Second-line chemotherapy for prostate cancer: patient characteristics and survival.

Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK.

Clin Prostate Cancer. 2005 Sep;4(2):86-90.

PMID:
16197608
21.

Compliance with a risk-factor-based guideline for the prevention of neonatal group B streptococcal sepsis.

Fleming MT, McDuffie RS, Russell K, Meikle S.

Infect Dis Obstet Gynecol. 1997;5(5):345-8.

22.

Righting reflexes and spontaneous locomotor activity during hypothermia.

Panuska JA, Kilcoyne JM, Fleming MT.

Cryobiology. 1969 Jul-Aug;6(1):37-41. No abstract available.

PMID:
5810547

Supplemental Content

Loading ...
Support Center